Honokiol Inhibits Bladder Cancer Cell Invasion Through Repressing SRC-3 Expression and Epithelial-mesenchymal Transition

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Sep 26

PMID 28943942

Citations 17

Authors

Lan Shen

Fang Zhang

Ruimin Huang

Jun Yan

Bing Shen

Affiliations

Soon will be listed here.

Abstract

Urinary bladder cancer (UBC) is one of the most common urological cancer types. Muscle invasive bladder cancer possesses high propensity for metastasis with poor prognosis. Honokiol is a lignan isolated from with high bioavailability and potent anticancer effects. The results of the present study demonstrated that honokiol significantly inhibited UBC cell migration and invasion in a dose-dependent manner compared with the vehicle-treated control group. In addition, honokiol treatment suppressed epithelial-mesenchymal transition by induction of E-cadherin and repression of N-cadherin. Honokiol was capable of significantly downregulating the expression of cell invasion-associated genes, steroid receptor coactivator-3 (SRC-3), matrix metalloproteinase (MMP)-2 and Twist1. Notably, the inhibition of UBC cell invasion by honokiol was reversed by reintroduction of oncoprotein SRC-3 expression, with the restoration of MMP-2 and Twist1, and reduction of E-cadherin expression. Furthermore, the results of the luciferase assay confirmed that SRC-3 could regulate Twist1 promoter activity. Taken together, the results of the present study suggest that honokiol is a promising agent against UBC cell invasion via downregulation of SRC-3 and its target genes.

Citing Articles

Integrative analyses of the transcriptome and metabolome reveal comprehensive mechanisms of monolignol biosynthesis in response to bioclimatic factors in Magnolia officinalis.

Zhong M, Wang Q, Tian H, Zhang B, Xu Z, Zhang Y BMC Plant Biol. 2024; 24(1):1210.

PMID: 39702009 PMC: 11657092. DOI: 10.1186/s12870-024-05933-5.

Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin.

Mikhaevich E, Sorokin D, Scherbakov A Res Pharm Sci. 2023; 18(5):580-591.

PMID: 37842518 PMC: 10568957. DOI: 10.4103/1735-5362.383712.

Comprehensive landscape of the ST3GAL family reveals the significance of ST3GAL6-AS1/ST3GAL6 axis on EGFR signaling in lung adenocarcinoma cell invasion.

Li J, Long Y, Sun J, Wu J, He X, Wang S Front Cell Dev Biol. 2022; 10:931132.

PMID: 36092699 PMC: 9462654. DOI: 10.3389/fcell.2022.931132.

Extraction Techniques and Analytical Methods for Isolation and Characterization of Lignans.

Patyra A, Koltun-Jasion M, Jakubiak O, Kiss A Plants (Basel). 2022; 11(17).

PMID: 36079704 PMC: 9460740. DOI: 10.3390/plants11172323.

Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling.

Qin T, Li J, Xiao Y, Wang X, Gong M, Wang Q Front Oncol. 2021; 11:728583.

PMID: 34671554 PMC: 8521150. DOI: 10.3389/fonc.2021.728583.

References

Avtanski D, Nagalingam A, Bonner M, Arbiser J, Saxena N, Sharma D . Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 2014; 8(3):565-80. PMC: 4009450. DOI: 10.1016/j.molonc.2014.01.004. View

Long W, Foulds C, Liu J, Ding C, Lonard D, Solis L . ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012; 122(5):1869-80. PMC: 3336992. DOI: 10.1172/JCI61492. View

Gheldof A, Berx G . Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013; 116:317-36. DOI: 10.1016/B978-0-12-394311-8.00014-5. View

Arora S, Singh S, Piazza G, Contreras C, Panyam J, Singh A . Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012; 12(10):1244-52. PMC: 3663139. DOI: 10.2174/156652412803833508. View

Louie M, Zou J, Rabinovich A, Chen H . ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol. 2004; 24(12):5157-71. PMC: 419858. DOI: 10.1128/MCB.24.12.5157-5171.2004. View

Jeong J, Lee J, Chang K, Kim H . Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int J Oncol. 2012; 41(4):1358-64. DOI: 10.3892/ijo.2012.1582. View

Tania M, Khan M, Fu J . Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35(8):7335-42. DOI: 10.1007/s13277-014-2163-y. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Guo S, Xu J, Xue R, Liu Y, Yu H . Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol. 2013; 19(2):319-24. DOI: 10.1007/s10147-013-0549-2. View

10.

Wang Y, Lonard D, Yu Y, Chow D, Palzkill T, Wang J . Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014; 74(5):1506-1517. PMC: 3947477. DOI: 10.1158/0008-5472.CAN-13-2939. View

11.

Hsu I, Yeh C, Slavin S, Miyamoto H, Netto G, Tsai Y . Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 2014; 5(17):7917-35. PMC: 4202170. DOI: 10.18632/oncotarget.1421. View

12.

Yan J, Tsai S, Tsai M . SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin. 2006; 27(4):387-94. DOI: 10.1111/j.1745-7254.2006.00315.x. View

13.

Liao L, Kuang S, Yuan Y, Gonzalez S, OMalley B, Xu J . Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid Biochem Mol Biol. 2003; 83(1-5):3-14. DOI: 10.1016/s0960-0760(02)00254-6. View

14.

Cai D, Shames D, Raso M, Xie Y, Kim Y, Pollack J . Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010; 70(16):6477-85. PMC: 2922434. DOI: 10.1158/0008-5472.CAN-10-0005. View

15.

Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M . Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008; 68(13):5460-8. PMC: 2826835. DOI: 10.1158/0008-5472.CAN-08-0955. View

16.

Zhang Q, Zhao W, Ye C, Zhuang J, Chang C, Li Y . Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget. 2015; 6(35):37335-48. PMC: 4741933. DOI: 10.18632/oncotarget.6135. View

17.

Anzick S, Kononen J, Walker R, Azorsa D, TANNER M, Guan X . AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997; 277(5328):965-8. DOI: 10.1126/science.277.5328.965. View

18.

Ahn K, Sethi G, Shishodia S, Sung B, Arbiser J, Aggarwal B . Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 2006; 4(9):621-33. DOI: 10.1158/1541-7786.MCR-06-0076. View

19.

Wang M, Zhao F, Li S, Chang A, Jia Z, Chen Y . AIB1 cooperates with ERα to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation. PLoS One. 2013; 8(6):e65556. PMC: 3676316. DOI: 10.1371/journal.pone.0065556. View

20.

Joo Y, Eun S, Park S, Lee J, Chang K, Kim H . Honokiol inhibits U87MG human glioblastoma cell invasion through endothelial cells by regulating membrane permeability and the epithelial-mesenchymal transition. Int J Oncol. 2013; 44(1):187-94. DOI: 10.3892/ijo.2013.2178. View